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Objective: We systematically reviewed clinical studies on the use of venous and arterial allografts for infrainguinal
revascularization. We attempted to find evidence for the best infrainguinal vascular allograft by a systematic review of the
available literature.
Methods: An electronic search of the MEDLINE, EMBASE, and Cochrane databases was used to determine key articles
from studies on the different types of vascular allografts used in infrainguinal reconstruction from 1966 to 2004. Articles
were independently reviewed by using previously defined inclusion and exclusion criteria. Study results were gathered
with cumulative primary patency as the primary end point. Secondary end points were major complications, graft
disintegration, and major limb loss. Quantitative analysis was performed on the prospective randomized trials, and linear
regression analysis was performed on cumulative primary patency. Fontaine’s classification system was applied.
Results:No systematic review of randomized controlled trials was found. Five randomized controlled trials, 3 prospective
cohort or case series, and 15 retrospective case series with 3837 vascular allografts were found. Methods of allograft
preservation were cryopreservation (5 studies), cold storage (3 studies), and glutaraldehyde preservation of human
umbilical veins (15 studies). One-year cumulative primary patency rates were 13% to 79% for cryopreservation, 63% to
80% for cold storage, and 40% to 91% for glutaraldehyde. The weighted mean 1-year cumulative primary graft patency
rate was 41% for cryopreservation, 71% for cold storage, and 70% for glutaraldehyde allografts. Four randomized trials
on femoropopliteal bypasses demonstrated higher patency rates of glutaraldehyde-preserved human umbilical veins than
polytetrafluoroethylene grafts. Statistical heterogeneity between studies (I2  91.4%) was too high to perform a formal
meta-analysis. The rate of major limb loss was 20% to 58% for cryopreservation, 10% to 69% for cold storage, and 0% to
65% for glutaraldehyde, and the percentage of graft disintegration was 2% to 6% for cryopreservation, 4% to 15% for cold
storage, and 0% to 11% for glutaraldehyde.
Conclusions: A firm conclusion could not be made because there were no studies available in which direct comparison was
performed between different preservation methods of vascular allografts. In addition, heterogeneity of the individual
studies hampered direct comparison of different types of vascular allografts. However, the overall graft performance of
glutaraldehyde-preserved human umbilical vein allografts may be superior to that of other vascular allografts. ( J Vasc
Surg 2006;44:518-24.)Autologous vein is the conduit of choice in patients
who need a bypass for critical lower leg ischemia. However,
suitable autologous veins may be of inferior quality or
absent as a result of prior use. Alternatives include pros-
thetic grafts (polytetrafluoroethylene [PTFE] and Dacron
[DuPont, Wilmington, Del]) or vascular allografts. Pros-
thetic vascular grafts have disappointing patency rates of
approximately 30% at 5 years in distal reconstructions and
cannot prevent limb loss inmany patients with critical lower
limb ischemia.1
Transplantation of a vascular allograft is an attractive
alternative in patients with no suitable autologous vein.
The technique of vascular transplantation was introduced
by Carrel and Guthrie in their classic studies of 1908.2 In
the mid-19th century, studies reported that large-caliber
vascular allografts could result in graft disruption, calcifica-
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518tion, and occlusion. As a consequence, large-caliber allo-
grafts were abandoned in favor of prosthetic grafts, which
performed satisfactorily in noninfected operative fields.
Currently, the large majority of allografts are used in in-
frainguinal vascular reconstructions.
Transplantation of blood vessels requires a suitable
graft preservation method. Improvements in tissue preser-
vation techniques allow a considerable number of blood
vessels of different lengths and diameters to be stored and
used whenever necessary.3 Over the past two decades, this
has led to a renewed interest in vascular allograft transplan-
tation of small-caliber grafts (6 mm) for peripheral vascu-
lar reconstructions.
The aim of this systematic review was to evaluate the
results of clinical studies in which vascular allografts were
used in the management of patients needing an infraingui-
nal bypass operation and to find evidence for the best
vascular preservation technique.
METHODS
Inclusion and exclusion criteria. Clinical studies of
patients with vascular allografts for infrainguinal arterial
obstructive disease (acute and chronic) were included. In
accordance with the recommendations of the Committee
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of North America, only series of at least 40 procedures were
included.4,5 Requirements were that the donor vessels
should be either arterial or venous segments and that the
method of preservation of the allograft should be men-
tioned. The arterial donor vessels had to be taken from the
iliac or femoropopliteal arteries, and the venous donor
vessels had to be taken from the saphenous vein or human
umbilical vein (HUV).
For inclusion, information on patency, location of the
anastomosis, and length of the follow-up period had to be
retrievable. Patency rates had to be based on objective
findings and had to have been demonstrated by an accepted
vascular imaging technique such as duplex scanning, arte-
riography, or magnetic resonance imaging. Composite
conduits were excluded. However, we did include the
Biograft (Meadox Medicals, Oakland, NJ)—an HUV allo-
graft externally reinforced by Dacron mesh—because there
is no contact between the luminal blood flow and the
prosthetic material. Studies on xenografts were excluded, as
were studies that included reconstructions for aneurysmal
disease, access for hemodialysis, or vascular trauma.
Cumulative primary graft patency was the primary end
point. Secondary end points were major complications,
graft disintegration, and major limb loss. Major limb loss
was defined as a below-knee or more proximal amputation.
Search strategy. Two authors (P.J.F. and M.M.I.) in-
dependently undertook an electronic search of MEDLINE
(January 1966 to January 2004), EMBASE (January 1988
to December 2003), the Cochrane Clinical Trials Register,
and the Cochrane Database of Systematic Reviews. No
language restrictions were enforced, and a manual cross-
reference search of key articles was performed to identify
additional relevant articles. The following keywords and
Medical Subject Heading terms were used: “peripheral
arterial occlusive disease,” “peripheral ischemic disease,”
“critical limb ischemia,” “infrainguinal repair,” “arterial
reconstruction,” “vascular reconstruction,” “transplanta-
tion,” “arterial graft,” “venous graft,” “arterial homograft,”
“vein homograft,” “arterial allograft,” “venous allograft,”
“autologous vein,” “patency,” “limb salvage,” “reopera-
tion,” “redo,” “amputation,” “fresh,” “cold storage,”
“4°C,” “cryopreservation,” “lyophilization,” and “glutar-
aldehyde.” The search commands were combined with the
maximally sensitive qualifying string for randomized con-
trolled trials (RCTs) as defined by the UK Cochrane Cen-
tre.6 The keywords and Medical Subject Heading terms
were combined with different suffixes to define the best fit
for the search question.
Data collection. Extracting patient data and graft
characteristics and deciding whether the studies met the
inclusion criteria were performed independently by two
authors (P.J.F. and M.M.I.). Patency data, as the primary
outcome, were collected at 1, 6, and 12 months and 2 to 3
years after surgery. The checklists of three working groups
on reporting standards served as guidelines to ensure that
all relevant data were gathered from the articles. These
groups were the Meta-analysis of Observational Studies inEpidemiology group,7 the Quality of Reporting of Meta-
analyses group,8 and the Consolidated Standards of Re-
porting Trials group.9
Statistical analysis. Quantitative data from the four
prospective RCTs were entered into Cochrane RevMan
4.2.7 software (The Cochrane Collaboration, Oxford, En-
gland) and analyzed with MetaView. If statistical heteroge-
neity (I2) was less than 60%, meta-analysis was planned.10
The weighted mean was calculated for 1-, 2-, and 3-year
cumulative primary graft patency for the nonrandomized
cohort studies. Weighted means were calculated by multi-
plying the outcome concerned by the number of allografts
included in each single study. These results were added up
and divided by the total number of allografts in the relevant
allograft preservation group. Linear regression analysis was
performed on the cumulative primary patency rates of all
studies after 24 months, and the percentage included pa-
tients with Fontaine stage II limb ischemia. The Pearson
correlation coefficient was calculated by SPSS 6.2 software
(SPSS Inc, Chicago, Ill).
RESULTS
Studies included. A total of 1260 publications were
found. They were all screened by title to see whether they
matched the inclusion criteria. If the relevance of an article
was unclear, the abstract was read, and information on
patients, type of bypass surgery, and graft type was col-
lected. This search yielded 81 articles that were then re-
viewed in detail for inclusion and exclusion criteria. A final
set of 23 key articles was obtained.11-33
No systematic review of RCTs on vascular allograft
preservation methods was retrieved. Four RCTs were re-
trieved that compared vascular allografts with alternative
conduit material for peripheral vascular bypass surgery.
These trials compared HUV allografts with PTFE and
autologous vein grafts,29,30,32,33 and they provided the
highest level of evidence available for the comparison of
the HUV allograft and prosthetic bypass (level Ib, ac-
cording to the Level of Evidence and Grades of Recom-
mendation as provided by the National Health Service
Centre for Evidence-Based Medicine). One RCT concern-
ing venous allografts looked at the effect of immunosup-
pressive therapy on graft patency.13 Three studies were
prospective cohort or case series, and the remaining studies
were retrospective case series containing level IV evidence.
Studies excluded. If patient series were published
more than once as a result of prolonged follow-up, only the
article with the longest follow-up was reviewed. Four re-
view articles dealing with synthetic grafts, xenografts, and
the financial aspects of vascular disease were excluded.
If identical studies from the same institution were re-
ported by different authors, they were included only once.
Two articles on lyophilization were excluded because of
small study groups. Studies on peripheral arterial recon-
structions using vascular allografts in combination with
nonallograft material were also excluded. One Japanese and
one Czech article were excluded because of translation
complications.
ilical v
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cular allograft preservation methods were used in the se-
lected studies: cryopreservation, cold storage, and glutaral-
dehyde preservation. Cryopreservation was used for both
arterial15 and venous11-14 allograft preservation. I n a l l cases,
cryopreservation was performed in a dimethyl sulfoxide–
containing solution by using a programmable control-rate
freezer. Storage temperatures ranged from 120°C to
196°C. Most grafts were obtained from Cryolife, Inc
(Kennesaw, Ga) and had an outer diameter of more than
3.5 mm. The storage, thawing, and handling protocols
provided by Cryolife have been established during the last
two decades. Cold storage was used in three studies, and all
of these were on venous allografts that were harvested
during varicose vein surgery.16-18 Diameters ranged from 6
to 9 mm, and lengths ranged from 30 to 65 cm. The grafts
were stored at 4°C in a saline solution containing antibiot-
ics (chloramphenicol and amphotericin). The veins were
examined under aseptic conditions for wall quality and
diameter measurement and were ready for use after 10 to
21 days. All articles about glutaraldehyde vascular allograft
preservation were studies in which the HUV was used as a
conduit. These grafts (Biograft) were manually prepared,
tanned with glutaraldehyde, and covered with a polyester
Dacron mesh. Storage was performed in 50% aqueous
Table I. General characteristics of the included studies of
Study Year
Inclusion
period
No.
grafts
Cryopreservation of venous allografts
Brockbank11 1992 1985-1990 75 
Martin12 1994 1987-1993 115 
Carpenter13 1997 2 y 40 
Farber14 2003 1992-2002 240 
Cryopreservation of arterial allografts
Branchereau15 2000 1991-1997 165* 
Cold storage of venous allografts
Reedt Dortland16 1991 1984-1989 156 
Rebane17 1997 1978-1993 107 
De Leersnijder18 1992 1982-1989 100 
Glutaraldehyde venous allografts (HUV)
Dardik19 1988 1975-1985 907 
Dardik20 1995 1985-1993 167 
Dardik21 2002 1990-2000 283 
Robison22 1983 1976-1981 99 
Hirsch23 1984 5 y 133 
Boontje24 1986 1978-1984 257 
Jarrett25 1989 1977-1986 211 
Batt26 1990 1978-1987 105 
Sato27 1995 1977-1993 111 
Comparison of HUV with other conduits
Weisel28 1981 1976-1979 66 
Eickhoff 29 1987 1980-1981 50 
McCollum30 1991 1984-1989 87 
Johnson31 1991 NR 55 
Johnson32 2000 1983-1988 261 
Aalders33 1992 1983-1984 47 
NR, Not reported; Retrosp, retrospective; CS, case series; AP, antiplatelet th
prospective; RCT, prospective randomized clinical trial; HUV, human umb
*Series included 45 grafts preserved by cold storage.ethanol. Just before implantation, grafts underwent a rinseprocedure. In most studies, the glutaraldehyde preserva-
tion protocol itself was not described in detail.
Baseline and outcome characteristics. Table I de-
scribes the baseline characteristics of the 23 key articles.
The publication year of the studies ranged from 1968 to
2002. Fifteen of these studies (68%) were published after
1990. A total of 3263 patients with 3837 vascular allografts
were included in this systematic review. Critical limb isch-
emia (CLI; Fontaine stage III-IV) was the indication for
vascular reconstruction in 78% (2927/3762) of the vascu-
lar allografts. The distal anastomosis was located crurally in
38% (1340/3527) and in the popliteal region in 57%
(2034/3592) of the procedures. Crural locations included
the tibial, peroneal, and pedal arteries. A popliteal anasto-
mosis was defined as being either above the knee or below
the knee.
Most studies were retrospective case series. Of the pro-
spective series, five were RCTs, two were case series, and one
was a cohort study. The only RCT performed on cryopre-
served allografts was that of Carpenter and Tomaszewski,13
which, after vascular allograft implantation, randomized
patients to either immunosuppressive therapy with azathio-
prine (17 patients) or no immunosuppressive therapy (23
patients). The overall cumulative primary graft patency rate
at 12 months was 13%, and there was no significant differ-
ial and venous infrainguinal allografts
itical
emia
Crural
anastomosis Anticoagulation
Study
design
R 39% NR Retrosp CS
0% 88% AP or AC Retrosp CS
0% 93% AP Prosp RCT
9% 65% AP or AC Retrosp CS
0% 79% AP and/or AC Retrosp CS
7% 33% AC Retrosp CS
0% 63% AC Retrosp CS
1% NR AC (26%) Retrosp CS
4% 36% NR Retrosp CS
9% 51% NR Retrosp CS
9% 61% AC Prosp CS
1% 79% BK NR Retrosp CS
3% 0% NR Retrosp CS
6% 38% NR Retrosp CS
3% 0% NR Retrosp CS
5% 50% AC Retrosp CS
1% NR NR Retrosp CS
8% 18% NR Prosp CHS
1% 0% NR Prosp RCT
3% 0% AP Prosp RCT
5% 25% NR Prosp CS
8% 0% AP Prosp RCT
3% 0% AC Prosp RCT
(aspirin and/or clopidogrel); AC, anticoagulant therapy (warfarin); Prosp,
ein; BK, below knee; CHS, prospective cohort study.arter
Cr
isch
N
8
10
8
10
6
10
4
9
8
8
9
6
2
7
9
3
6
8
7
8
6
2
erapyence between the groups. Four RCTs were retrieved on
t, disin
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conduits in femoropopliteal bypasses. Eickhoff et al29 pub-
lished amulticenter trial comparingHUV and PTFE grafts.
They demonstrated a 1-year cumulative primary patency
rate of 74% for the HUV grafts compared with 55% for the
PTFE grafts (81% CLI). Aalders and van Vroonhoven33
reported a study of above-knee femoropopliteal bypass
grafts only (23% CLI) in which the 6-year cumulative
primary patency rates of PTFE and HUV grafts were 38%
and 71%, respectively. Johnson and Squires32 compared
above-knee femoropopliteal bypasses using autologous sa-
phenous vein, PTFE, and HUV. The cumulative primary
patency rates after 5 years were 73%, 39%, and 53%, respec-
tively. McCollum et al30 compared HUV grafts with PTFE
grafts (CLI 73%). The 1-year cumulative primary patency
rates in this study were 68% for HUV and 61% for PTFE.
Table II describes the clinical outcomes of the allografts
in the 23 key articles. The data on graft patency were
extracted directly from the text or graphs. Only five articles
had follow-up periods of longer than five years. The 1-year
cumulative primary patency of cryopreserved venous allo-
grafts ranged from 13% to 79%. There was only one key
article on cryopreserved arterial allografts, with a reported
1-year cumulative primary patency of 49%. Key articles on
cold storage as amethod of vascular preservation concerned
venous allografts only. The 1-year cumulative primary pa-
tency of cold-stored venous allografts ranged from 63% to
80%, and for glutaraldehyde-preserved venous allografts, it
Table II. Clinical characteristics of allografts and patient o
Study
Cum prim (sec) patency
1 mo 6 mo 1 y
Brockbank11 94 87 79 
Martin12 — 59 (59) 37 (40) 
Carpenter13 — — 13 
Farber14 83 (83) 50 (52) 30 (30) 
Branchereau15 83 (90) — 49 (60) 
Weighted mean 1-y cum prim patency 41
Reedt Dortland16 — 89 80 
Rebane17 83 — 65 
De Leersnijder18 — 79 63 
Weighted mean 1-y cum prim patency 71
Dardik19 83 67 59 
Dardik20 86 84 80 
Dardik21 — — 84 (87) 
Robison22 86 69 64 
Hirsch23 91 81 73 
Boontje24 96 — 86 
Jarrett25 90 (85) 83 (78) 78 (70) 
Batt26 61 — 42 
Sato27 94 87 86 
Weisel28 70 49 40 
Eickhoff 29 —  78 75
McCollum30 — 78 68 
Johnson31 — — 63 
Johnson32 — 77 74 
Aalders33 — 96 (96) 91 (92) 
Cum, Cumulative; prim, primary; sec, secondary; compl, complication; disinranged from 40% to 91%. The weighted mean 1-year and2- to 3-year cumulative primary graft patency rate was 41%
and 31% for cryopreserved allografts, 71% and 51% for
cold-stored allografts, and 70% and 56% for glutaraldehyde
allografts, respectively.
Postoperative follow-up information on 30-day post-
operative mortality, major complications, major limb loss,
and graft disintegration was collected. Postoperative mor-
tality was not reported in nine of the key articles. The
overall postoperative mortality in the remaining 14 articles
was 2.9% (51/1744). Major complications included graft-
related complications such as infection requiring graft re-
moval, hemorrhage that necessitated reoperation, and non–
graft-related complications such as myocardial infarction,
pulmonary embolism, stroke, deep venous thrombosis, and
gastrointestinal hemorrhage. The reported incidences of
major complications were between 0% and 15%.Major limb
loss occurred in 0% to 69% of the patients after graft
implantation. Graft disintegration (aneurysm formation or
graft rupture) was not reported in 5 of the 23 key articles
but occurred in 0% to 15% of grafts.
In the analysis of the four RCTs concerning HUV
allografts vs PTFE and saphenous vein, the weighted mean
difference could not be calculated in two RCTs because the
standard deviation was not reported. Statistical heteroge-
neity (I2) was 91.4%. This was far above the accepted
maximum level of 60% for performing a meta-analysis;
therefore, it was not appropriate to perform ameta-analysis.
A significant positive correlation existed between the
mes
Mortality
30 d
Major
compl
Major
limb loss
Graft
disint2-3 y
79 NR NR NR NR
9 (28) 0% 0% 27% 2%
— 3% 15% 58% 3%
8 (20) 6% 11% 33% 4%
5 (42) 3% 1% 20% 6%
62 NR 4% 10% 15%
38 4% 1% 69% 4%
46 4% NR 15% 15%
43 NR 4% 35% 2%
65 NR 4% 38% 3%
7 (74) NR 3% 35% 0.4%
43 2% NR 29% NR
69 7% 2% NR
70 1% NR NR 1%
3 (59) 1% 6% 10% NR
33 6% 7% 65% 8%
79 NR 1% NR 10%
36 5% NR NR NR
53 NR 0% 4% 0%
57 NR 1% 14% NR
49 NR NR 5% 7%
64 1% 3% 10% 0.4%
6 (89) 0% 0% 0% 11%
tegration; NR, not reported.utco
1
1
3
6
6
8percentage of patients with Fontaine stage II disease and
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Pearson correlation coefficient was 0.58, significant at the
0.01 level.
DISCUSSION
In this review we included 23 studies in which 3 differ-
ent methods of vascular allograft preservation were used.
Because 15 of the 23 studies were retrospective case series,
the level of evidence of most studies in this review was low,
and, as a consequence, results are susceptible to bias. We
tried to minimize bias by using objective criteria for impor-
tant outcome parameters and did not impose any restric-
tions on the language of publication in the initial search.
Because of the heterogeneity in various clinical factors, such
as indication for operation, level of distal anastomosis,
anticoagulation use, and high statistical heterogeneity, it
was not appropriate to perform an overall meta-analysis of
the studies.
The reported incidences of major complications were
relatively low (0%-15%). Two studies on cryopreserved
venous allografts13,14 showed the highest major complica-
tion rates to be 11% and 15% (Table II). This is reflected by
the high mean age and the large number of patients with
substantial renal dysfunction in the series of Farber et al14
and the high percentage of CLI (100%) and previous
peripheral bypass procedures shown in the series of Carpen-
ter and Tomaszewski.13 In most series (12/21), the distal
anastomosis was situated in the infrapopliteal or cruropedal
artery in more than 50% of cases. Reported major limb loss
varied widely from 0% to 69% and was highest in the cold
storage venous allografts described by Rebane et al.17
Albers et al1 performed a meta-analysis on 43 studies of
PTFE bypass grafts to infrapopliteal arteries and reported a
pooled estimate of foot preservation of 66% after 3 years of
Fig. Plot of linear regression analysis of number of patients with
Fontaine stage II and overall 2-year cumulative primary graft
patency rate of all included studies. Pearson correlation coeffi-
cient  0.58 (P  .01).follow-up. Of the studies in our review, 67% (12/18)reported a higher percentage of foot preservation. In an-
other meta-analysis, Albers et al34 reviewed 33 studies of
patients with an infrapopliteal allograft bypass, and the
pooled 1-year foot preservation rate was between 70% and
80%. If a patient with limb ischemia needs a bypass to the
popliteal artery, the most suitable type of graft to use is still
open to debate. In the Cochrane Review, Mamode and
Scott35 were unable to demonstrate any clear evidence in
support of the use of a particular type of graft at this level.
Yet a recent randomized trial clearly favored autologous
saphenous vein over PTFE grafts.36 If a patient needs a
crural bypass, the Transatlantic Inter-Society Consensus
Working Group37 recommend the use of good-quality autol-
ogous vein to construct the bypass. They based their find-
ings on evidence from a meta-analysis by Hunink et al,38
with 5-year primary patency rates for infrageniculate recon-
structions of 66% for autologous vein and 33% for PTFE.
Whether the addition of a distal cuff in PTFE grafts or a
distal arteriovenous fistula will ultimately result in an im-
proved patency of infrainguinal PTFE grafts is still to be
defined.39-41 Fifteen of the 23 series included looked at
venous allografts preserved in glutaraldehyde (HUV), and
the highest patency rates were reported in this group (range,
33%-89%). With the exception of Brockbank et al,11 studies
in which cryopreserved venous allografts were used re-
ported the lowest patency rates. Because of the high per-
centage of patients lost to follow-up (92% after 2 years), the
results of this study should be interpreted cautiously. No
studies that included different types of allografts or graft
preservation methods were available, so direct comparison
between various vascular allografts or preservation tech-
niques was not possible.
Because of heterogeneity among studies, as reflected in
differing levels of preoperative critical ischemia, percent-
ages of crural anastomosis, and differences in the number of
patients lost to follow-up, it can be argued that weighted
mean cumulative primary patency rate is inappropriate for
comparing the results of the different allografts. However,
comparison of patency rates is essential when deciding
which allograft to use. Because the patency rate is an
important characteristic of graft function, the weighted
mean primary patency used in this review is currently the
best approach when comparing the results of these allo-
grafts with the data available in the literature.
Graft disintegration is a particular problem in cold-
stored venous allografts. The degree of antigenicity of the
vascular allograft plays a role in the process of biodegrada-
tion, as shown in reconstructions with bovine heterografts.
The preservation technique is important in diminishing the
rejection response to the allograft. It has been shown that
the glutaraldehyde molecule masks the histocompatibility
antigen sites on vascular tissue,21 and it has been suggested
that cryopreservation decreases the acceptor immunologic
response against venous allografts.42 This probably explains
the lower biodegradation rate of glutaraldehyde and cryo-
preserved vascular allografts in comparison with cold-
stored grafts.
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important issues in vascular transplantation.Most studies in
our review report the results of allotransplantations per-
formed without ABO blood type matching. The role of
tissue matching in the function of vascular allografts is still
to be defined. Only one study randomized for immunosup-
pressive therapy,13 and it was demonstrated that immuno-
suppression had no effect on the patency of cryopreserved
allografts. It has been demonstrated that cryopreserved and
cold-stored allografts retain cell-surface structures such as
the major histocompatibility complex that are involved in
the process of allograft rejection.
The ideal vascular allograft should have a high graft
patency rate, a low graft disintegration rate, need no im-
munosuppressive therapy, be available off the shelf in dif-
ferent diameters and lengths, and be able to be stored for
long periods. This systematic review addressed the various
aspects of vascular allografts. Because of recent advances in
preservation of vascular allografts and the expected intro-
duction of these new vascular allografts for use in clinical
vascular surgery, their results needs to be compared with
those described in this systematic review.43,44
In conclusion, this systematic review assessed the re-
sults of studies on infrainguinal vascular allografts. Differ-
ent allograft preservation methods were compared, and it
was demonstrated that heterogeneity among studies was
high and excluded a formal meta-analysis. A firm conclu-
sion could not be made because there were no studies
available in which direct comparison was performed be-
tween different preservation methods of vascular allografts.
However, this review revealed that patency rates for infrain-
guinal reconstructions performed by using allografts were
satisfactory. If the results of major complications, limb loss,
and graft disintegration were also taken into account, glu-
taraldehyde preservation of HUV allografts seemed supe-
rior to the other methods of vascular allograft preservation.
We are grateful to Dr D. Th. Ubbink for assistance in
statistical and meta-analysis.
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